Clinical Trials Logo
  1. Home
  2. Metastatic Colon Cancer
  3. NCT02291744

A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients

Metastatic Colon Cancer Clinical Trial

Official title:
A Randomized Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients With Unresectable Metastatic Lesions

Clinical Trial Summary

The primary endpoint is to evaluate the TFS (time to failure of strategy).

Clinical Trial Description

The primary endpoint is to evaluate the time to failure of strategy, that is the second progression time after induction therapy by the use of XELOX regimen, comparing XELOX regimen chemotherapy combined with or without surgical resection of the primary lesion from the time of randomization to maintenance therapy and reapplication of induction therapy, or time to the use of second line strategy (if no reapplication of induction therapy) or time to no further treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02291744
Study type Interventional
Source Fudan University
Contact Weijian Guo, doctor
Phone 13816066360
Email mingzhuhuang0718@163.com
Status Recruiting
Phase Phase 2
Start date October 2014
Completion date October 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04186117 - Development of Clinical and Biological Database in Colorectal Cancer N/A
Completed NCT05468892 - Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Completed NCT03176485 - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors N/A
Recruiting NCT05983367 - A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer Phase 2
Recruiting NCT03730558 - ZETA : Prospective Observational Study
Recruiting NCT06180460 - CALM: Managing Distress in Malignant Brain Cancer N/A
Active, not recruiting NCT03251378 - A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer Phase 1
Recruiting NCT04737213 - SGM-101 in Colorectal Lung Metastases Phase 2
Recruiting NCT05714124 - Liver Embolization Approaches for Tumor Management
Recruiting NCT05396807 - REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients N/A
Active, not recruiting NCT02724202 - Curcumin in Combination With 5FU for Colon Cancer Early Phase 1
Withdrawn NCT03764137 - Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05848739 - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors Phase 1
Not yet recruiting NCT06202183 - Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial N/A
Withdrawn NCT01936961 - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors N/A
Not yet recruiting NCT06358677 - Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer Phase 2
Completed NCT03415126 - A Study of ASN007 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02834052 - Pembrolizumab + Poly-ICLC in MRP Colon Cancer Phase 1/Phase 2
Recruiting NCT03694938 - Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients N/A